WO2000043548A1 - Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer - Google Patents

Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer Download PDF

Info

Publication number
WO2000043548A1
WO2000043548A1 PCT/US2000/001599 US0001599W WO0043548A1 WO 2000043548 A1 WO2000043548 A1 WO 2000043548A1 US 0001599 W US0001599 W US 0001599W WO 0043548 A1 WO0043548 A1 WO 0043548A1
Authority
WO
WIPO (PCT)
Prior art keywords
pacp
cellular
cells
protein
expression
Prior art date
Application number
PCT/US2000/001599
Other languages
English (en)
French (fr)
Inventor
Ming-Fong Lin
Original Assignee
Board Of Regents Of The University Of Nebraska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents Of The University Of Nebraska filed Critical Board Of Regents Of The University Of Nebraska
Priority to AU32127/00A priority Critical patent/AU3212700A/en
Priority to US09/889,630 priority patent/US7094533B1/en
Publication of WO2000043548A1 publication Critical patent/WO2000043548A1/en
Priority to US11/507,256 priority patent/US20060294615A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03002—Acid phosphatase (3.1.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/US2000/001599 1999-01-21 2000-01-21 Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer WO2000043548A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU32127/00A AU3212700A (en) 1999-01-21 2000-01-21 Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
US09/889,630 US7094533B1 (en) 1999-01-21 2000-01-21 Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
US11/507,256 US20060294615A1 (en) 1999-01-21 2006-08-21 Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11655199P 1999-01-21 1999-01-21
US60/116,551 1999-01-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/507,256 Division US20060294615A1 (en) 1999-01-21 2006-08-21 Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer

Publications (1)

Publication Number Publication Date
WO2000043548A1 true WO2000043548A1 (en) 2000-07-27

Family

ID=22367878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001599 WO2000043548A1 (en) 1999-01-21 2000-01-21 Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer

Country Status (2)

Country Link
AU (1) AU3212700A (un)
WO (1) WO2000043548A1 (un)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051172A1 (en) * 2004-11-11 2006-05-18 Chempath Oy Method for testing a compound for a therapeutic effect and a diagnostic method
WO2008112283A2 (en) * 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
CN113455465A (zh) * 2021-06-29 2021-10-01 安徽省立医院(中国科学技术大学附属第一医院) 人前列腺癌LNCaP细胞裸鼠皮下移植模型的构建方法
CN113711991A (zh) * 2020-11-02 2021-11-30 江门赛尔康生物科技有限公司 一种以pap为靶点的药物筛选动物模型的构建方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5763202A (en) * 1988-06-03 1998-06-09 Cytogen Corporation Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells
US5773215A (en) * 1989-10-24 1998-06-30 Board Of Regents, The University Of Texas System Tumor marker protein for cancer risk assessment
US5882864A (en) * 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763202A (en) * 1988-06-03 1998-06-09 Cytogen Corporation Methods of detecting prostate carcinoma using a monoclonal antibody to a new antigenic marker in epithelial prostatic cells alone or with a monoclonal antibody to an antigen of LNCaP cells
US5773215A (en) * 1989-10-24 1998-06-30 Board Of Regents, The University Of Texas System Tumor marker protein for cancer risk assessment
US5935818A (en) * 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US5882864A (en) * 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OSTANIN K. ET AL.: "Heterologous Expression of Human Prostatic Acid Phosphatase and Site-directed Mutagenesis of the Enzyme Active Site", THE JOURNAL OF BIOLOGICAL CHEMISTRY,, vol. 269, no. 12, 25 March 1994 (1994-03-25), pages 8971 - 8978, XP002927979 *
PORVARI K. ET AL.: "Differential Androgen Regulation of Rat Prostatic Acid Phosphatase Transcripts", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,, vol. 213, no. 3, 24 August 1995 (1995-08-24), pages 861 - 868, XP002927980 *
SHARIEF ET AL.: "Nucleotide Sequence of human Prostatic Acid Phosphatase ACPP Gene, Including seven Alu Repeats", BIOCHEM AND MOL. BIOL. INTERNATIONAL,, vol. 33, no. 3, June 1994 (1994-06-01), pages 561 - 565, XP002927978 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051172A1 (en) * 2004-11-11 2006-05-18 Chempath Oy Method for testing a compound for a therapeutic effect and a diagnostic method
US7919671B2 (en) 2004-11-11 2011-04-05 Chempath Oy Method for testing a compound for a therapeutic effect and a diagnostic method
WO2008112283A2 (en) * 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
WO2008112283A3 (en) * 2007-03-12 2009-03-26 Us Gov Health & Human Serv Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
CN113711991A (zh) * 2020-11-02 2021-11-30 江门赛尔康生物科技有限公司 一种以pap为靶点的药物筛选动物模型的构建方法和应用
CN113455465A (zh) * 2021-06-29 2021-10-01 安徽省立医院(中国科学技术大学附属第一医院) 人前列腺癌LNCaP细胞裸鼠皮下移植模型的构建方法
CN113455465B (zh) * 2021-06-29 2023-02-28 安徽省立医院(中国科学技术大学附属第一医院) 人前列腺癌LNCaP细胞裸鼠皮下移植模型的构建方法

Also Published As

Publication number Publication date
AU3212700A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
US20060294615A1 (en) Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
KR100887164B1 (ko) Ｌｉｐｇ 폴리펩타이드의 활성을 증가시키고 초저밀도 지단백질(ｖｌｄｌ) 콜레스테롤 및 저밀도 지단백질(ｌｄｌ) 콜레스테롤의 수준을 저하시키는 조성물 및 이를 위해 유용한 화합물을 동정하는 방법
Lloyd et al. Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells
Gilpin et al. A novel, secreted form of human ADAM 12 (meltrin α) provokes myogenesis in vivo
US7008776B1 (en) Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US7592319B2 (en) Uses of DNA-PK
Ghosh et al. PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation
US5747660A (en) Nucleic acid encoding prostaglandin F2α receptor regulatory protein
KR100516561B1 (ko) 사람 리파제-유사 유전자에 의해 암호화된 폴리펩타이드, 조성물 및 방법
WO2000043548A1 (en) Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
CA2253433A1 (en) Mammalian regulator of nonsense-mediated rna decay
WO1996015242A2 (en) Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
EP1090146A1 (en) Uses of dna-pk
WO1994009037A9 (en) A NEW CLASS OF RPTPases: THEIR STRUCTURAL DOMAINS AND LIGANDS
Wei et al. Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.
US7745579B1 (en) Inhibitor of NF-KB activation
JP2003189883A (ja) 新規ユビキチン特異プロテアーゼ
CA2183900A1 (en) Agents for the pre-symptomatic detection, prevention and treatment of breast cancer in humans
Mandal et al. Molecular characterization of murine pancreatic phospholipase A2
JP2001500847A (ja) 癌の検出および処置の新規方法
US6916473B2 (en) Isolated human lipase proteins, nucleic acid molecules encoding human lipase proteins, and uses thereof
Acid et al. Overexpression of the Retinoic Acid-responsive Gene Stra6 in
Shan Transcriptional regulation of the human prostatic acid phosphatase gene: tissue-specific and androgen-dependent regulation of the promoter constructs in cell lines and transgenic mice
CA2419251A1 (en) Nucleic acid constructs including a novel t-cell active promoter, and pharmaceutical compositions and methods utilizing same for regulating t-cell mediated immune response
Xing Biological effects of PEA3 expression in HER-2/neu-overexpressing human cancer cells and the molecular mechanisms of PEA3-mediated transcriptional repression on HER-2/neu

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09889630

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase